Pre-treatment expression levels of BCL-2 in melanoma patient samples inversely correlated with tumor response after BRAF inhibition (Figures 1A and 1B), while pretreatment levels of the other assayed BCL-2 family members had no correlation with outcome (Figure S1). The gene discussed is BRAF; the disease is melanoma.